OM
Opaleye Management Portfolio holdings
AUM
$758M
1-Year Est. Return
124.8%
This Fund
S&P 500
1 Year Est. Return
+124.8%
AUM
$758M
AUM Growth
+$493K
(+0.07%)
Holding
62
Top Buys
| 1 | +$23.3M | |
| 2 | +$15.3M | |
| 3 | +$14.7M | |
| 4 |
MeiraGTx Holdings
MGTX
|
+$13.2M |
| 5 |
Q32 Bio
QTTB
|
+$4.95M |
Top Sells
| 1 | +$47.2M | |
| 2 | +$20.1M | |
| 3 | +$17.9M | |
| 4 |
Alkermes
ALKS
|
+$13.7M |
| 5 |
Ocular Therapeutix
OCUL
|
+$9.48M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BBOT
51
BridgeBio Oncology
BBOT
$719M
| $477K | 0.06% |
+53,282
|
|
||
|
LBRX
52
LB Pharmaceuticals
LBRX
$802M
| $358K | 0.05% |
+14,506
|
|
||
|
ADGM
53
Adagio Medical Holdings
ADGM
$16.1M
| $21.2K | ﹤0.01% |
18,444
|
|
||
|
54
Alkermes
ALKS
$7.03B
| – | – |
-490,000
|
|
||
55
BridgeBio Pharma
BBIO
$13B
| – | – |
-18,319
|
|
||
|
GBIO
56
DELISTED
Generation Bio
GBIO
| – | – |
-310,000
|
|
||
57
Gossamer Bio
GOSS
$54.2M
| – | – |
-2,720,000
|
|
||
58
Karyopharm Therapeutics
KPTI
$206M
| – | – |
-930,000
|
|
||
|
RAPT
59
DELISTED
RAPT Therapeutics
RAPT
| – | – |
-150,000
|
|
||
|
SLN
60
Silence Therapeutics
SLN
$326M
| – | – |
-78,926
|
|
||
|
VTYX
61
DELISTED
Ventyx Biosciences
VTYX
| – | – |
-251,932
|
|
||
62
Zymeworks
ZYME
$1.85B
| – | – |
-108,929
|
|